ABBV is trading near $208, well below the low analyst target of $223, with RSI in oversold territory and price under the 50‑day moving average, hinting at a potential technical bounce. Given the recent dip‑buy narrative and oversold technicals, we shift from bearish to a neutral stance.

Headlines are championing AbbVie as a “no‑brainer” dip buy and note FDA progress on testosterone therapy, energizing investor sentiment. This upbeat coverage moves our view to bullish from the prior bearish tone.

AbbVie’s expanding immunology pipeline and entry into the thyroid‑eye disease market improve long‑term growth prospects, yet cash‑flow pressure and execution risk remain concerns. Consequently, we adjust from bearish to a cautiously neutral outlook.

Technical data shows the 10‑day SMA crossing above the 20‑day SMA, a rising volume trend, and a positive MACD histogram, signaling short‑term bullish momentum. The price still sits about 8% under the low analyst target, but we upgrade to bullish based on these signals.